SONESITATUG VEDOTIN GRANTED PRIORITY REVIEW IN THE US FOR 2ND AND LATER-LINE TREATMENT OF PATIENTS WITH CLDN18.2-POSITIVE ADVANCED GASTRIC/GEJ CANCERS

Reuters · 3d ago

Please log in to view news